[37, 38] Myeloma cell‐derived RUNX2 promotes myeloma progression,[39] and the hypermethylation or alteration of RUNX2 contributes to B‐cell lineage resistance.[40, 41]JUNB can protect MM cells against Vd‐induced cell death.[42]BCL2 is a common, highly expressed prosurvival (antiapoptotic) protein in neoplastic plasma cells.[43] In summary, activating the transcription of these oncogenes directly regulated by POU2F2 results in drug resistance. The gene discussed is BCL2; the disease is plasma cell myeloma.